JPWO2019209940A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019209940A5 JPWO2019209940A5 JP2020559388A JP2020559388A JPWO2019209940A5 JP WO2019209940 A5 JPWO2019209940 A5 JP WO2019209940A5 JP 2020559388 A JP2020559388 A JP 2020559388A JP 2020559388 A JP2020559388 A JP 2020559388A JP WO2019209940 A5 JPWO2019209940 A5 JP WO2019209940A5
- Authority
- JP
- Japan
- Prior art keywords
- adhesive composition
- composition according
- delivery device
- transdermal delivery
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 63
- 239000000853 adhesive Substances 0.000 claims description 59
- 230000001070 adhesive effect Effects 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 23
- 208000013403 hyperactivity Diseases 0.000 claims description 23
- 230000037317 transdermal delivery Effects 0.000 claims description 21
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 16
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 16
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical group C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- 229960005333 tetrabenazine Drugs 0.000 claims description 7
- 206010008748 Chorea Diseases 0.000 claims description 6
- 239000004593 Epoxy Substances 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 208000012601 choreatic disease Diseases 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- -1 fatty acid esters Chemical class 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 208000012661 Dyskinesia Diseases 0.000 claims description 5
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 5
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 5
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
- 208000016620 Tourette disease Diseases 0.000 claims description 5
- 208000018839 Wilson disease Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims description 4
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 4
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 4
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims description 4
- 229920003085 Kollidon® CL Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 claims description 4
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 claims description 4
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- 229920000578 graft copolymer Polymers 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- YRDNVESFWXDNSI-UHFFFAOYSA-N n-(2,4,4-trimethylpentan-2-yl)prop-2-enamide Chemical compound CC(C)(C)CC(C)(C)NC(=O)C=C YRDNVESFWXDNSI-UHFFFAOYSA-N 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- 229920003082 Povidone K 90 Polymers 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229920003174 cellulose-based polymer Polymers 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000004899 motility Effects 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662456P | 2018-04-25 | 2018-04-25 | |
| US62/662,456 | 2018-04-25 | ||
| PCT/US2019/028900 WO2019209940A1 (en) | 2018-04-25 | 2019-04-24 | Tetrabenazine transdermal delivery device |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522240A JP2021522240A (ja) | 2021-08-30 |
| JP2021522240A5 JP2021522240A5 (https=) | 2022-04-20 |
| JPWO2019209940A5 true JPWO2019209940A5 (https=) | 2022-04-20 |
| JP7386544B2 JP7386544B2 (ja) | 2023-11-27 |
Family
ID=68295781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559388A Active JP7386544B2 (ja) | 2018-04-25 | 2019-04-24 | テトラベナジン経皮送達デバイス |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12144899B2 (https=) |
| EP (1) | EP3784237B1 (https=) |
| JP (1) | JP7386544B2 (https=) |
| KR (1) | KR102952482B1 (https=) |
| CN (1) | CN112165942B (https=) |
| AU (1) | AU2019261403B2 (https=) |
| BR (1) | BR112020021700A2 (https=) |
| CA (1) | CA3097189A1 (https=) |
| DK (1) | DK3784237T3 (https=) |
| ES (1) | ES2968827T3 (https=) |
| IL (1) | IL278185B2 (https=) |
| MX (1) | MX2020011269A (https=) |
| TW (1) | TWI832854B (https=) |
| WO (1) | WO2019209940A1 (https=) |
| ZA (1) | ZA202006415B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784237B1 (en) | 2018-04-25 | 2023-11-01 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| US20220362165A1 (en) * | 2019-10-22 | 2022-11-17 | Shinkei Therapeutics Llc | Tetrabenazine transdermal delivery device |
| IL296624A (en) * | 2020-03-30 | 2022-11-01 | Shinkei Therapeutics Inc | Transdermal delivery of dextromethorphan |
| CN116036055A (zh) * | 2023-03-16 | 2023-05-02 | 上海世领制药有限公司 | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63313723A (ja) | 1987-06-16 | 1988-12-21 | Nitto Electric Ind Co Ltd | 外用貼付剤 |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| JP4988080B2 (ja) * | 1997-09-05 | 2012-08-01 | 日東電工株式会社 | 経皮吸収型製剤 |
| IL135258A0 (en) | 1997-09-26 | 2001-05-20 | Noven Pharma | Bioadhesive compositions and methods for topical administration of active agents |
| WO2002024157A2 (en) * | 2000-09-19 | 2002-03-28 | National Starch And Chemical Investment Holding Corporation | Acryl adhesive useful in transdermal drug delivery systems |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| TW200628175A (en) | 2004-10-08 | 2006-08-16 | Noven Pharma | Transdermal drug delivert device including an occlusive backing |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20120208773A1 (en) * | 2008-08-12 | 2012-08-16 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenazine |
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2771539A1 (en) | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
| DE102010024105A1 (de) | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP2872126B1 (en) * | 2012-07-16 | 2017-12-06 | Grünenthal GmbH | Pharmaceutical patch for transdermal administration of tapentadol |
| US9682068B2 (en) | 2013-05-20 | 2017-06-20 | Mylan Inc. | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders |
| WO2014195352A1 (en) | 2013-06-04 | 2014-12-11 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system |
| EA201691512A1 (ru) | 2014-01-27 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 |
| NZ760790A (en) | 2014-02-07 | 2022-11-25 | Neurocrine Biosciences Inc | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| WO2015171802A1 (en) * | 2014-05-06 | 2015-11-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| AR098771A1 (es) * | 2014-12-16 | 2016-06-15 | Amarin Tech S A | Un dispositivo para la administración transdérmica de rotigotina |
| HRP20221106T1 (hr) | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| EA036837B1 (ru) | 2015-06-23 | 2020-12-25 | Нейрокрин Байосайенсиз, Инк. | Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| CN107028916B (zh) * | 2016-02-04 | 2020-05-12 | 北京泰德制药股份有限公司 | 含有布比卡因或其药用盐的皮肤外用制剂 |
| ITUB20161016A1 (it) * | 2016-02-24 | 2017-08-24 | Emenem Srl | Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| CN110678181A (zh) | 2017-04-01 | 2020-01-10 | 阿德普蒂奥制药有限公司 | (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途 |
| US20190111035A1 (en) | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| TWI741168B (zh) * | 2017-04-28 | 2021-10-01 | 日商日東電工股份有限公司 | 經皮吸收製劑 |
| WO2019016357A1 (en) | 2017-07-20 | 2019-01-24 | Neurolixis | USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS |
| GB2565049B (en) | 2017-07-27 | 2020-06-10 | Reckitt Benckiser Health Ltd | A head assembly of a dermaplaning device |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| EP3784237B1 (en) | 2018-04-25 | 2023-11-01 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| US20190374521A1 (en) | 2018-06-10 | 2019-12-12 | Axsome Therapeutics, Inc. | Methods of modulating tetrabenazine metabolites plasma levels using bupropion |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
-
2019
- 2019-04-24 EP EP19792500.1A patent/EP3784237B1/en active Active
- 2019-04-24 CN CN201980035258.6A patent/CN112165942B/zh active Active
- 2019-04-24 KR KR1020207032380A patent/KR102952482B1/ko active Active
- 2019-04-24 TW TW108114349A patent/TWI832854B/zh active
- 2019-04-24 ES ES19792500T patent/ES2968827T3/es active Active
- 2019-04-24 IL IL278185A patent/IL278185B2/en unknown
- 2019-04-24 BR BR112020021700-0A patent/BR112020021700A2/pt unknown
- 2019-04-24 JP JP2020559388A patent/JP7386544B2/ja active Active
- 2019-04-24 CA CA3097189A patent/CA3097189A1/en active Pending
- 2019-04-24 AU AU2019261403A patent/AU2019261403B2/en active Active
- 2019-04-24 MX MX2020011269A patent/MX2020011269A/es unknown
- 2019-04-24 US US17/050,230 patent/US12144899B2/en active Active
- 2019-04-24 WO PCT/US2019/028900 patent/WO2019209940A1/en not_active Ceased
- 2019-04-24 DK DK19792500.1T patent/DK3784237T3/da active
-
2020
- 2020-10-15 ZA ZA2020/06415A patent/ZA202006415B/en unknown
-
2024
- 2024-10-10 US US18/911,581 patent/US20250144045A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7153010B2 (ja) | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | |
| US10987316B2 (en) | Compositions and methods for transdermal delivery of tertiary amine drugs | |
| JP4925823B2 (ja) | プラミペキソール活性剤を含む経皮治療システム | |
| US20160331762A1 (en) | Transdermal testosterone device and delivery | |
| CA2896336C (en) | Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents | |
| JP2021522240A5 (https=) | ||
| US11337936B2 (en) | Amphetamine transdermal compositions with acrylic block copolymer | |
| US11376327B2 (en) | Stable transdermal amphetamine compositions and methods of manufacture | |
| US8852628B1 (en) | Transdermal drug delivery system for diclofenac | |
| US20220023425A1 (en) | Stretchable backing layers for transdermal drug delivery systems | |
| IL278185B1 (en) | Tetrabenazine transdermal delivery device | |
| US20170112781A1 (en) | Transdermal drug delivery systems with polyisobutylene face adhesive | |
| US20140336253A1 (en) | Composition for transdermal administration of rivastigmine | |
| JPWO2019209940A5 (https=) | ||
| US20150209302A1 (en) | Adhesive skin patch | |
| KR100563194B1 (ko) | 펜타닐을 유효성분으로 함유하는 경피투여제제 | |
| RU2020138298A (ru) | Устройство для трансдермальной доставки тетрабеназина | |
| KR20130049353A (ko) | 펜타닐을 함유하는 경피투여용 패취시스템 | |
| JPWO2021081022A5 (https=) | ||
| US20180036319A1 (en) | Transdermal drug delivery systems for norethindrone acetate | |
| JPWO2019201755A5 (https=) | ||
| JP2021515791A5 (https=) | ||
| JPWO2019175106A5 (https=) | ||
| JPWO2021078761A5 (https=) |